Innovative COPD treatment Anoro Ellipta Makes China's National Reimbursement Drug List (NRDL)

GlaxoSmithKline (GSK) announced today that its dual bronchodilators treatment Anoro Ellipta (Umeclidinium/Vilanterol) for chronic obstructive pulmonary disease (COPD) was officially added to the 2019 National Reimbursement Drug List (NRDL) of China. 

The latest data shows that ~100 million Chinese patients are living with COPD. Moreover, the prevalence has significantly increased in recent years from 8.2% in 2002 to 13.7% for people at 40 and older1,2. Due to the low awareness and the low diagnosis rate for the disease, COPD has become the third leading cause of death by disease in China, presenting a huge public health challenge3.

Widely recognised around the world, Anoro Ellipta has been approved for launch in 98 countries and regions while covered by insurance in 47 countries and regions. 

Besides Anoro Ellipta on the NRDL for the first time, GSK also successfully renewed the contract with the government for its first-line antidepressant drug Seroxat CR, enabling more patients with depression to benefit from this innovative drug. 

Dr. Fabio Landazabal, Senior Vice President of Emerging Markets and Chairman of GSK China, said: “Under Chinese government’s progressive healthcare reform, not only the review and approval process of innovative drugs has been greatly accelerated, we also see more and more newly launched drugs are able to timely enter the NRDL. The successful inclusion of Anoro Ellipta into NRDL this time has displayed joint efforts of various parties and confirmed GSK’s unwavering commitment of ‘in China, with China and for China’. We will continue to support the Chinese government’s healthcare reform and expand the accessibility and affordability of innovative drugs by adhering to the innovation-based and patient-focused values, working together for the shared vision of ‘Healthy China 2030’.” 

Xinguang Wang, Vice President of Corporate Affairs, Market Access and Commercial Operation at GSK, said: “The Chinese government has been striving for enlarging the NRDL by taking in more innovative drugs. It’s very encouraging to see another GSK's innovative drug Anoro Ellipta is available now for more Chinese patients because of these efforts. On the one hand, it’s our patients’ desperate need to have access to the most innovative and cost-effective drugs in the shortest time. On the other hand, working with the government to expand the accessibility and affordability of innovative drugs has always been on the top of GSK’s practice which demonstrates our long-term commitment to the Chinese patients. In the future, we look forward to strengthening our partnership with the government so that more and more Chinese patients can benefit from our innovative drugs.”

 

About GSK:

One of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit www.gsk.com

 

GSK enquiries:

Summer Li(summer.n.li@gsk.com

 

References:

  1. Zhong N, et al. Am J Respir Crit Care Med. 2007;176(8):753-760.
  2. Wang C. et al. The Lancet 2018; 391 (10131).
  3. Zhou M, et al. Lancet. 2019 Jun 24. pii S0140-6736(19)30427-1.